The publisher explores Seagen’s prescription pharmaceutical performance and outlook over 2019-29.
Snapshot
Model updates (4 November 2020)
Model updates (31 July 2020)
Model updates (30 April 2020)
Model updates (6 February 2020)
Snapshot
- Overview - Seagen is poised for continued growth.
- Key themes - [1] Adcetris growth is slowing due to increasing market penetration and inroads from competing products like Keytruda [2] Launch of Padcev and Tukysa will drive further growth in 2020 and beyond [3] Collaborative licensing agreements with large pharmaceutical companies provide diversified sources of revenue.
Model updates (4 November 2020)
- Adcetris forecast adjusted lower due to sales trends
- Padcev forecast adjusted higher due to recent data in MIBC and long-term guidance given by Astellas
- Tukysa forecast adjusted higher due to launch trends.
Model updates (31 July 2020)
- Padcev forecast adjusted higher due to continued strong launch trends
- Tukysa forecast adjusted higher due to strong initial launch
- Tisotumab vedotin forecast added after results of innovaTV 204 trial.
Model updates (30 April 2020)
- Padcev forecast adjusted higher due to strong initial launch
- Tucatinib name changed to Tukysa; forecast adjusted higher due to earlier-than-expected approval.
Model updates (6 February 2020)
Table of Contents
Company Background
Recent Earnings Review
Company Forecast
Company Profile
Clinical Trial Overview
